<p>Perkins Coie Trust Co 在最近向证券交易委员会的披露中表示，在第三季度将其在美敦力 PLC (NYSE:MDT - 免费报告) 的持股减少了 96.5%。该公司在季度内出售了 1,115,440 股后，持有 39,985 股这家医疗科技公司的股票。根据其最近的 SEC 文件，Perkins Coie Trust Co 在美敦力的持股价值为 3,808,000 美元。</p>
<ul>
<li>美敦力股票找到了立足点——现在正在获得动能</li>
</ul>
<p>其他几家对冲基金最近也调整了对 MDT 的持股。Brighton Jones LLC 在第四季度将其在美敦力的持股提升了 1,368.0%。Brighton Jones LLC 现在拥有 39,989 股这家医疗科技公司的股票，价值 3,194,000 美元，此前在上个季度又增持了 37,265 股。T. Rowe Price Investment Management Inc. 在第一季度购买了美敦力的新股份，价值约 286,000 美元。Martingale Asset Management L P 在第一季度将其在美敦力的持股提高了 674.9%。Martingale Asset Management L P 现在拥有 37,762 股这家医疗科技公司的股票，价值 3,393,000 美元，此前在上个季度又购买了 32,889 股。Price T Rowe Associates Inc. MD 在第一季度将其在美敦力的持股提高了 42.9%。Price T Rowe Associates Inc. MD 现在拥有 10,059,135 股这家医疗科技公司的股票，价值 903,915,000 美元，此前在上个季度又购买了 3,017,849 股。最后，Summit Financial LLC 在第一季度将其在美敦力的持股提高了 10.9%。Summit Financial LLC 现在拥有 22,556 股这家医疗科技公司的股票，价值 2,027,000 美元，此前在上个季度又购买了 2,226 股。机构投资者和对冲基金持有该公司 82.06% 的股份。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票研究分析师最近对该股票发布了报告。Wall Street Zen 在周六将美敦力的评级从 “持有” 上调至 “买入”。Cowen 在 11 月 14 日的研究报告中重申了对美敦力的 “买入” 评级。Truist Financial 在周四将美敦力的目标价从 110.00 美元下调至 107.00 美元，并对该公司设定了 “持有” 评级。Citigroup 在 10 月 7 日的报告中将美敦力的目标价从 101.00 美元上调至 112.00 美元，并给予该股票 “买入” 评级。最后，摩根士丹利在 11 月 19 日的研究报告中将美敦力的目标价从 107.00 美元上调至 117.00 美元，并给予该公司 “增持” 评级。一位研究分析师对该股票给予了强烈买入评级，十三位给予了买入评级，十二位给予了持有评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 109.94 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 08/18 - 08/22</li>
</ul>
<p><strong>查看我们关于美敦力的最新报告</strong></p>
<h2>关于美敦力的热门头条</h2>
<p>以下是本周影响美敦力的主要新闻：</p>
<ul>
<li>积极情绪：美敦力提交了 S-1 文件，计划将其糖尿病部门 MiniMed 上市——首选的分拆路径是首次公开募股（IPO）后再进行分拆。管理层表示，此举是计划分拆的一部分，旨在创建两家专注的公司，从而释放价值并提供战略清晰度。美敦力宣布提交糖尿病业务 MiniMed 的 IPO 注册声明</li>
<li>积极情绪：监管和产品进展：美敦力（及其同行）获得了 FDA 对液体栓塞系统的批准——这提醒我们，该公司继续推进能够支持有机增长的治疗设备，超越糖尿病分拆。美敦力和强生医疗科技均获得 FDA 对液体栓塞系统的批准</li>
<li>中性情绪：所有权和结构细节可能限制短期财务影响——媒体报道指出，美敦力预计将保留多数投票控制权（报告显示至少约 80.1% 的投票股票），这表明 IPO 可能更多是关于战略聚焦和价值实现，而非完全剥离。美敦力分拆 MiniMed 提交 IPO</li>
<li>中性情绪：分析师态度依然谨慎：一些公司（如 Robert W. Baird）维持 “持有” 评级，反映出即使战略举措展开，短期观点仍然混合。Robert W. Baird 对美敦力（MDT）维持持有评级</li>
<li>消极情绪：目标价下调：Truist 将其 MDT 目标价小幅下调（从 110 美元降至 107 美元）并维持 “持有” 评级，表明一些分析师认为尽管战略分拆，但短期内上涨空间有限。这一分析师行动可能会限制动能，直到 MiniMed 的财务状况和分拆机制更清晰为止。美敦力的目标价在 Truist 被下调至 107 美元，原为 110 美元。</li>
</ul>
<h2>美敦力股票表现</h2>
<ul>
<li>美敦力：收入投资者的机会变得更好</li>
</ul>
<p>NYSE:MDT 周五开盘价为 98.63 美元。该公司的 50 日移动平均线为 97.38 美元，200 日移动平均线为 93.35 美元。美敦力 PLC 的 1 年低点为 79.29 美元，1 年高点为 106.33 美元。该公司的债务与股本比率为 0.57，流动比率为 2.42，速动比率为 1.80。该公司的市值为 1264.5 亿美元，市盈率为 26.59，PEG 比率为 2.59，贝塔值为 0.71。</p>
<p>美敦力（NYSE:MDT - 获取免费报告）最近于 11 月 18 日（星期二）发布了季度财报。这家医疗技术公司报告本季度每股收益为 1.36 美元，超出市场普遍预期的 1.31 美元，超出幅度为 0.05 美元。美敦力的净利润率为 13.71%，股本回报率为 14.86%。该公司本季度的收入为 89.6 亿美元，而分析师预计为 88.6 亿美元。去年同期，该公司每股收益为 1.26 美元。本季度的收入较去年同期增长了 6.6%。美敦力已将 2026 财年的每股收益指导目标设定为 5.620-5.660 美元。分析师预测美敦力 PLC 今年的每股收益将为 5.46 美元。</p>
<h2>美敦力分红公告</h2>
<p>该公司最近宣布了季度分红，将于 1 月 16 日（星期五）支付。12 月 26 日（星期五）登记在册的股东将获得 0.71 美元的分红。这相当于年化分红为 2.84 美元，分红收益率为 2.9%。该分红的除息日为 12 月 26 日（星期五）。美敦力的分红支付比率为 76.55%。</p>
<h2>美敦力公司简介</h2>
<p>（免费报告）</p>
<p>美敦力公司是一家全球医疗技术公司，开发和制造广泛的治疗设备和医疗保健解决方案。公司合法总部位于爱尔兰，主要运营办公室位于美国，向全球医院、医生和医疗系统销售产品，自 1949 年成立以来，已发展成为服务全球医疗市场的最大医疗设备制造商之一。</p>
<p>美敦力的产品涵盖多个临床领域，包括心脏节律和心力衰竭（心脏起搏器、植入式心脏复律除颤器及相关心脏治疗）、微创和外科技术（腹腔镜和先进能量设备、可视化系统及外科创新）、修复治疗（脊柱和骨科、神经调节和神经血管治疗）以及糖尿病管理（胰岛素输送系统和血糖监测解决方案）。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，而非美敦力</li>
<li>如何做空纳斯达克：简单易懂的指南</li>
<li>耐克财报超预期，但在中国市场面临挑战并遭遇关税</li>
<li>澳大利亚证券交易所（ASX）是什么</li>
<li>人工智能热潮是泡沫吗？这两只分红股票表示不是</li>
<li>现在购买宝洁公司股票，在其创下新高之前</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
<p><strong>想知道其他对美敦力持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取美敦力 PLC（NYSE:MDT - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在美敦力吗？</h2>
<p>在考虑美敦力之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而美敦力并不在名单上。</p>
<p>虽然美敦力目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

美敦力

<p>Perkins Coie Trust Co 在第三季度将其在美敦力（Medtronic PLC）的持股减少了 96.5%，将持股量降至 39,985 股，价值 3,808,000 美元。其他几家对冲基金也调整了在美敦力的持股。分析师对该股票的评级不一，有的维持 “持有” 评级，有的则给予 “买入” 评级。美敦力计划通过首次公开募股（IPO）将其糖尿病部门 MiniMed 上市，旨在创建两家专注的公司。该公司还获得了 FDA 对液体栓塞系统的批准</p>

<p>Perkins Coie Trust Co decreased its stake in Medtronic PLC (NYSE:MDT - Free Report) by 96.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 39,985 shares of the medical technology company's stock after selling 1,115,440 shares during the quarter. Perkins Coie Trust Co's holdings in Medtronic were worth $3,808,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Perkins Coie Trust Co 在最近向证券交易委员会的披露中表示，在第三季度将其在美敦力 PLC (NYSE:MDT - 免费报告) 的持股减少了 96.5%。该公司在季度内出售了 1,115,440 股后，持有 39,985 股这家医疗科技公司的股票。根据其最近的 SEC 文件，Perkins Coie Trust Co 在美敦力的持股价值为 3,808,000 美元。</p>
</div><ul>
<li>Medtronic Stock Finds Its Footing—Now It’s Gaining Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>美敦力股票找到了立足点——现在正在获得动能</li>
</ul>
</div><p>Several other hedge funds have also recently modified their holdings of MDT. Brighton Jones LLC lifted its position in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock valued at $3,194,000 after acquiring an additional 37,265 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Medtronic during the first quarter worth approximately $286,000. Martingale Asset Management L P raised its stake in Medtronic by 674.9% in the 1st quarter. Martingale Asset Management L P now owns 37,762 shares of the medical technology company's stock valued at $3,393,000 after purchasing an additional 32,889 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Medtronic by 42.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,059,135 shares of the medical technology company's stock valued at $903,915,000 after purchasing an additional 3,017,849 shares during the last quarter. Finally, Summit Financial LLC lifted its holdings in Medtronic by 10.9% in the 1st quarter. Summit Financial LLC now owns 22,556 shares of the medical technology company's stock valued at $2,027,000 after purchasing an additional 2,226 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也调整了对 MDT 的持股。Brighton Jones LLC 在第四季度将其在美敦力的持股提升了 1,368.0%。Brighton Jones LLC 现在拥有 39,989 股这家医疗科技公司的股票，价值 3,194,000 美元，此前在上个季度又增持了 37,265 股。T. Rowe Price Investment Management Inc. 在第一季度购买了美敦力的新股份，价值约 286,000 美元。Martingale Asset Management L P 在第一季度将其在美敦力的持股提高了 674.9%。Martingale Asset Management L P 现在拥有 37,762 股这家医疗科技公司的股票，价值 3,393,000 美元，此前在上个季度又购买了 32,889 股。Price T Rowe Associates Inc. MD 在第一季度将其在美敦力的持股提高了 42.9%。Price T Rowe Associates Inc. MD 现在拥有 10,059,135 股这家医疗科技公司的股票，价值 903,915,000 美元，此前在上个季度又购买了 3,017,849 股。最后，Summit Financial LLC 在第一季度将其在美敦力的持股提高了 10.9%。Summit Financial LLC 现在拥有 22,556 股这家医疗科技公司的股票，价值 2,027,000 美元，此前在上个季度又购买了 2,226 股。机构投资者和对冲基金持有该公司 82.06% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Medtronic from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday. Cowen reaffirmed a &#34;buy&#34; rating on shares of Medtronic in a research note on Friday, November 14th. Truist Financial cut their price objective on shares of Medtronic from $110.00 to $107.00 and set a &#34;hold&#34; rating for the company in a report on Thursday. Citigroup boosted their target price on Medtronic from $101.00 to $112.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, October 7th. Finally, Morgan Stanley upped their price target on Medtronic from $107.00 to $117.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $109.94.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对该股票发布了报告。Wall Street Zen 在周六将美敦力的评级从 “持有” 上调至 “买入”。Cowen 在 11 月 14 日的研究报告中重申了对美敦力的 “买入” 评级。Truist Financial 在周四将美敦力的目标价从 110.00 美元下调至 107.00 美元，并对该公司设定了 “持有” 评级。Citigroup 在 10 月 7 日的报告中将美敦力的目标价从 101.00 美元上调至 112.00 美元，并给予该股票 “买入” 评级。最后，摩根士丹利在 11 月 19 日的研究报告中将美敦力的目标价从 107.00 美元上调至 117.00 美元，并给予该公司 “增持” 评级。一位研究分析师对该股票给予了强烈买入评级，十三位给予了买入评级，十二位给予了持有评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 109.94 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 08/18 - 08/22</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 08/18 - 08/22</li>
</ul>
</div><p><strong>Check Out Our Latest Report on Medtronic</strong></p>
<div class="lb-trans"><p><strong>查看我们关于美敦力的最新报告</strong></p>
</div><h2>Trending Headlines about Medtronic</h2>
<div class="lb-trans"><h2>关于美敦力的热门头条</h2>
</div><p>Here are the key news stories impacting Medtronic this week:</p>
<div class="lb-trans"><p>以下是本周影响美敦力的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Medtronic filed an S-1 to take its Diabetes unit, MiniMed, public — the preferred separation path is an IPO followed by a split-off. Management says the move is part of a planned separation aimed at creating two focused companies, which could unlock value and provide strategic clarity. Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed</li>
<li>Positive Sentiment: Regulatory and product progress: Medtronic (and peers) secured FDA nods for liquid embolic systems — a reminder the company continues to advance therapeutic devices that can support organic growth beyond the diabetes separation. Medtronic, J&amp;J MedTech both get FDA nods for liquid embolic systems</li>
<li>Neutral Sentiment: Ownership and structure details may limit immediate financial impact — media reports note Medtronic expects to retain majority voting control (reported at least ~80.1% of voting stock), suggesting the IPO could be more about strategic focus and value crystallization than a full divestiture. Medtronic Spin-Off MiniMed Files for IPO</li>
<li>Neutral Sentiment: Analyst stances remain cautious: some firms (e.g., Robert W. Baird) are maintaining &#34;hold&#34; ratings, reflecting mixed near-term views even as the strategic move unfolds. Robert W. Baird Remains a Hold on Medtronic (MDT)</li>
<li>Negative Sentiment: Price-target trim: Truist cut its MDT price target modestly (from $110 to $107) and kept a &#34;hold&#34; rating, a sign some analysts see limited near-term upside despite the strategic separation. This analyst action could cap momentum until clearer financials for MiniMed and separation mechanics are disclosed. Medtronic price target lowered to $107 from $110 at Truist</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：美敦力提交了 S-1 文件，计划将其糖尿病部门 MiniMed 上市——首选的分拆路径是首次公开募股（IPO）后再进行分拆。管理层表示，此举是计划分拆的一部分，旨在创建两家专注的公司，从而释放价值并提供战略清晰度。美敦力宣布提交糖尿病业务 MiniMed 的 IPO 注册声明</li>
<li>积极情绪：监管和产品进展：美敦力（及其同行）获得了 FDA 对液体栓塞系统的批准——这提醒我们，该公司继续推进能够支持有机增长的治疗设备，超越糖尿病分拆。美敦力和强生医疗科技均获得 FDA 对液体栓塞系统的批准</li>
<li>中性情绪：所有权和结构细节可能限制短期财务影响——媒体报道指出，美敦力预计将保留多数投票控制权（报告显示至少约 80.1% 的投票股票），这表明 IPO 可能更多是关于战略聚焦和价值实现，而非完全剥离。美敦力分拆 MiniMed 提交 IPO</li>
<li>中性情绪：分析师态度依然谨慎：一些公司（如 Robert W. Baird）维持 “持有” 评级，反映出即使战略举措展开，短期观点仍然混合。Robert W. Baird 对美敦力（MDT）维持持有评级</li>
<li>消极情绪：目标价下调：Truist 将其 MDT 目标价小幅下调（从 110 美元降至 107 美元）并维持 “持有” 评级，表明一些分析师认为尽管战略分拆，但短期内上涨空间有限。这一分析师行动可能会限制动能，直到 MiniMed 的财务状况和分拆机制更清晰为止。美敦力的目标价在 Truist 被下调至 107 美元，原为 110 美元。</li>
</ul>
</div><h2>Medtronic Stock Performance</h2>
<div class="lb-trans"><h2>美敦力股票表现</h2>
</div><ul>
<li>Medtronic: The Opportunity Gets Healthier for Income Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>美敦力：收入投资者的机会变得更好</li>
</ul>
</div><p>NYSE:MDT opened at $98.63 on Friday. The company's 50-day moving average is $97.38 and its two-hundred day moving average is $93.35. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The firm has a market capitalization of $126.45 billion, a price-to-earnings ratio of 26.59, a PEG ratio of 2.59 and a beta of 0.71.</p>
<div class="lb-trans"><p>NYSE:MDT 周五开盘价为 98.63 美元。该公司的 50 日移动平均线为 97.38 美元，200 日移动平均线为 93.35 美元。美敦力 PLC 的 1 年低点为 79.29 美元，1 年高点为 106.33 美元。该公司的债务与股本比率为 0.57，流动比率为 2.42，速动比率为 1.80。该公司的市值为 1264.5 亿美元，市盈率为 26.59，PEG 比率为 2.59，贝塔值为 0.71。</p>
</div><p>Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the previous year, the company earned $1.26 EPS. The business's revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.</p>
<div class="lb-trans"><p>美敦力（NYSE:MDT - 获取免费报告）最近于 11 月 18 日（星期二）发布了季度财报。这家医疗技术公司报告本季度每股收益为 1.36 美元，超出市场普遍预期的 1.31 美元，超出幅度为 0.05 美元。美敦力的净利润率为 13.71%，股本回报率为 14.86%。该公司本季度的收入为 89.6 亿美元，而分析师预计为 88.6 亿美元。去年同期，该公司每股收益为 1.26 美元。本季度的收入较去年同期增长了 6.6%。美敦力已将 2026 财年的每股收益指导目标设定为 5.620-5.660 美元。分析师预测美敦力 PLC 今年的每股收益将为 5.46 美元。</p>
</div><h2>Medtronic Dividend Announcement</h2>
<div class="lb-trans"><h2>美敦力分红公告</h2>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic's dividend payout ratio is 76.55%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度分红，将于 1 月 16 日（星期五）支付。12 月 26 日（星期五）登记在册的股东将获得 0.71 美元的分红。这相当于年化分红为 2.84 美元，分红收益率为 2.9%。该分红的除息日为 12 月 26 日（星期五）。美敦力的分红支付比率为 76.55%。</p>
</div><h2>Medtronic Company Profile</h2>
<div class="lb-trans"><h2>美敦力公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.</p>
<div class="lb-trans"><p>美敦力公司是一家全球医疗技术公司，开发和制造广泛的治疗设备和医疗保健解决方案。公司合法总部位于爱尔兰，主要运营办公室位于美国，向全球医院、医生和医疗系统销售产品，自 1949 年成立以来，已发展成为服务全球医疗市场的最大医疗设备制造商之一。</p>
</div><p>Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).</p>
<div class="lb-trans"><p>美敦力的产品涵盖多个临床领域，包括心脏节律和心力衰竭（心脏起搏器、植入式心脏复律除颤器及相关心脏治疗）、微创和外科技术（腹腔镜和先进能量设备、可视化系统及外科创新）、修复治疗（脊柱和骨科、神经调节和神经血管治疗）以及糖尿病管理（胰岛素输送系统和血糖监测解决方案）。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Medtronic</li>
<li>How to Short Nasdaq: An Easy-to-Follow Guide</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>Buy P&amp;G Now, Before It Sets A New All-Time High</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非美敦力</li>
<li>如何做空纳斯达克：简单易懂的指南</li>
<li>耐克财报超预期，但在中国市场面临挑战并遭遇关税</li>
<li>澳大利亚证券交易所（ASX）是什么</li>
<li>人工智能热潮是泡沫吗？这两只分红股票表示不是</li>
<li>现在购买宝洁公司股票，在其创下新高之前</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding MDT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对美敦力持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取美敦力 PLC（NYSE:MDT - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=MDT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Medtronic Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在美敦力吗？</h2>
</div><p>Before you consider Medtronic, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑美敦力之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而美敦力并不在名单上。</p>
</div><p>While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然美敦力目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Perkins Coie 信托公司减少了对美敦力公司（Medtronic PLC）的持股 $MDT